CURE CHILDHOOD CANCER, INC.

AUDITED FINANCIAL STATEMENTS

June 30, 2016 and 2015

CURE CHILDHOOD CANCER, INC. AUDITED FINANCIAL STATEMENTS June 30, 2016 and 2015

Independent Auditor's Report	1
Statements of Financial Position	2
Statements of Activities	3
Statements of Functional Expenses	5
Statements of Cash Flows	7
Notes to Financial Statements	8



To the Board of Directors Cure Childhood Cancer, Inc. Atlanta, GA

Independent Auditor's Report

We have audited the accompanying financial statements of CURE Childhood Cancer, Inc. (a nonprofit organization), which comprise the statements of financial position as of June 30, 2016 and 2015, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error, In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CURE Childhood Cancer, Inc. as of June 30, 2016 and 2015, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

The Lewis CPA her he

THE LEWIS CPA FIRM, INC.

January 6, 2017

678.990.9082 678.990.9086 FAX 1200 Abernathy Road, Suite 1700 Atlanta, GA 30328

CURE CHILDHOOD CANCER, INC. STATEMENTS OF FINANCIAL POSITION

June 30,	2016	2015
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$2,040,522	\$1,772,843
Accounts receivable	77,878	52,645
Prepaid expenses	22,000	22,000
Unconditional promises to give, due in one year		
TOTAL CURRENT ASSETS	2,140,400	1,847,488
FIXED ASSETS		
Furniture and equipment	19,461	19,461
Allowance for depreciation	(16,709)	(14,953)
TOTAL FIXED ASSETS	2,752	4,508
OTHER ASSETS		
Investments	978,114	1,023,160
Deposit	5,178	5,178
Intangibles, net of amortization	23,500	197
TOTAL OTHER ASSETS	1,006,792	1,028,535
TOTAL ASSETS	\$3,149,944	\$2,880,531
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable	\$29,447	\$32,068
Refundable advances	206,427	73,075
Grants payable, due in one year	220,226	774,949
Family funds held in trust		23,938
TOTAL CURRENT LIABILITIES	456,100	904,030
Grants payable, due in 2 years		81,281
Accrued salary	40,580	
Deferred lease incentives	2,456	13,033
TOTAL LIABILITIES	499,136	998,344
NET ASSETS		
Undesignated	823,826	37,038
Board-designated quasi-endowment	1,794,931	1,814,334
Unrestricted	2,618,757	1,851,372
Temporarily restricted	14,251	13,015
Permanently restricted	17,800	17,800
TOTAL NET ASSETS	2,650,808	1,882,187
TOTAL LIABILITIES AND NET ASSETS	\$3,149,944	\$2,880,531

CURE CHILDHOOD CANCER, INC. STATEMENT OF ACTIVITIES

For the year ended June 30,

2016

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
SUPPORT AND OTHER REVENUE Grants and contributions	¢2 228 725	¢9 27 (14		¢1 066 240
	\$3,228,735 798,244	\$837,614		\$4,066,349 798,244
Special events, net of direct benefits of \$229,761 In-kind goods and services	235,652			235,652
Program support	6,389			6,389
riogram support	0,303			0,309
	4,269,020	837,614	-	5,106,634
Investment returns Interest and dividends	40,724	699		41,423
Realized gains (losses)	3,701	099		3,701
Unrealized gains (losses)	(42,815)			(42,815)
Investment fees	(16,315)			(16,315)
	(14,705)	699	_	(14,006)
Net assets released from restrictions	(14,705)	0))	-	(14,000)
Restrictions satisfied by payments	837,077	(837,077)		-
Restretions subside by payments	001,011	(057,077)		
TOTAL SUPPORT AND OTHER REVENUE	5,091,392	1,236	-	5,092,628
EXPENSES				
Program Services				
Research	1,454,158			1,454,158
Fellowships	376,755			376,755
Education	782,003			782,003
Patient and Family Support	1,083,638			1,083,638
Total Program Services	3,696,554			3,696,554
Supporting Services				
General and administrative expenses	290,348			290,348
Fundraising	337,105			337,105
Total Supporting Services	627,453			627,453
TOTAL EXPENSES	4,324,007			4,324,007
CHANGE IN NET ASSETS	767,385	1,236	-	768,621
NET ASSETS, BEGINNING OF YEAR	1,851,372	13,015	\$17,800	1,882,187
NET ASSETS, END OF YEAR	\$2,618,757	\$14,251	\$17,800	2,650,808

CURE CHILDHOOD CANCER, INC. STATEMENT OF ACTIVITIES

For the year ended June 30,

2015

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
	Childstitetta	nestretta	Restricted	10000
SUPPORT AND OTHER REVENUE				
Grants and contributions	\$2,870,208	\$475,102		\$3,345,310
Special events, net of direct benefits of \$202,444	741,288			741,288
In-kind goods and services	117,208			117,208
Program support	7,936			7,936
	3,736,640	475,102	-	4,211,742
Investment returns Interest and dividends	54,261	882		55,143
Realized gains (losses)	120,261	002		120,261
Unrealized gains (losses)	(189,447)			(189,447)
Investment fees	(17,408)			(17,408)
	(32,333)	882		(31,451)
Net assets released from restrictions	(52,555)	002	-	(31,431)
Restrictions satisfied by payments	799,940	(799,940)		-
TOTAL SUPPORT AND OTHER REVENUE	4,504,247	(323,956)	-	4,180,291
EXPENSES				
Program Services				
Research	2,727,416			2,727,416
Fellowships	411,448			411,448
Education	642,782			642,782
Patient and Family Support	935,685			935,685
Total Program Services	4,717,331			4,717,331
Supporting Services				
General and administrative expenses	298,044			298,044
Fundraising	211,419			211,419
Total Supporting Services	509,463			509,463
TOTAL EXPENSES	5,226,794			5,226,794
CHANGE IN NET ASSETS	(722,547)	(323,956)	-	(1,046,503)
NET ASSETS, BEGINNING OF YEAR	2,573,919	336,971	\$17,800	2,928,690
NET ASSETS, END OF YEAR	\$1,851,372	\$13,015	\$17,800	\$1,882,187

CURE CHILDHOOD CANCER, INC. STATEMENT OF FUNCTIONAL EXPENSES

				Patient and	General and		
	Research	Fellowships	Education	Family Support	Administrative	Fundraising	Total
EXPENSES							
Grants	\$1,454,158	\$376,755		\$160,959			\$1,991,872
Salaries, payroll taxes, and fringe benefits			\$283,684	521,536	\$141,718	\$206,236	1,153,174
Professional fees			206,360		23,248		229,608
In-kind goods and services				167,783	2,000	33,769	203,552
Community education			186,264		5,346	1,123	192,733
Events				73,631		46,877	120,508
Patient and Family Support Programs				94,398			94,398
Occupancy			20,761	37,637	9,997	15,898	84,293
Bank charges/credit card fees					73,578		73,578
Newsletter			69,956				69,956
Information systems			3,650	6,617	17,154	18,191	45,612
Miscellaneous			3,532	6,941	11,915	2,704	25,092
Supplies			2,210	4,007	1,064	8,030	15,311
Telephone			2,688	4,873	2,290	2,058	11,909
Insurance			2,417	4,382	1,808	1,851	10,458
Depreciation			481	874	230	368	1,953
Amortization							
TOTAL EXPENSES	\$1,454,158	\$376,755	\$782,003	\$1,083,638	\$290,348	\$337,105	\$4,324,007
INVESTMENT FEES					\$16,315		\$16,315

The accompanying notes are an integral part of these financial statements.

5

CURE CHILDHOOD CANCER, INC. STATEMENT OF FUNCTIONAL EXPENSES

	Research	Followshing	Education	Patient and	General and Administrative	Fundacióno	Total
	Research	Fellowships	Education	Family Support	Administrative	Fundraising	Total
EXPENSES							
Grants	\$2,727,416	\$411,448		\$119,655			\$3,258,519
Salaries, payroll taxes, and fringe benefits			\$224,556	491,150	\$156,912	\$83,090	955,708
Professional fees			183,198		22,166	252	205,616
In-kind goods and services				111,708		5,500	117,208
Community education			145,699				145,699
Events				59,448		84,838	144,286
Patient and Family Support Programs				80,777			80,777
Occupancy			19,509	39,691	11,908	6,601	77,709
Bank charges/credit card fees					64,832		64,832
Newsletter			53,474				53,474
Information systems			5,133	10,444	24,241	22,844	62,662
Miscellaneous			2,150	4,374	12,453	728	19,705
Supplies			2,104	4,280	1,284	5,212	12,880
Telephone			3,425	6,969	2,091	1,159	13,644
Insurance			2,951	6,003	1,801	998	11,753
Depreciation			498	1,013	304	169	1,984
Amortization			85	173	52	28	338
TOTAL EXPENSES	\$2,727,416	\$411,448	\$642,782	\$935,685	\$298,044	\$211,419	\$5,226,794
INVESTMENT FEES					\$17,408		\$17,408

CURE CHILDHOOD CANCER, INC. STATEMENTS OF CASH FLOWS

For the years ended June 30,	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$768,621	(\$1,046,503)
Adjustments to reconcile change in net assets		
to net cash provided by (used in) operating activities:		
Realized (gains)/losses on investments	(3,701)	(120,261)
Unrealized (gains)/losses on investments	42,815	189,447
Loss on disposal of fixed assets		2,936
Donated Stock	(66,314)	(25,013)
Deferred lease incentives	(10,577)	(8,772)
Depreciation and amortization	1,953	2,322
(Increase) decrease in:		
Accounts receivable	(25,233)	(21,376)
Prepaid expenses		36,825
Unconditional promises to give		60,000
Increase (decrease) in:		(82,000)
Accounts payable	(2,621)	(82,909)
Grants payable Refundable advances	(636,004)	856,230
	133,352	68,300
Family funds held in trust Accrued salary	(23,938) 40,580	(1,809)
Accided salary	40,300	
NET CASH PROVIDED BY (USED IN)		
OPERATING ACTIVITIES	218,933	(90,583)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of fixed assets & intangibles	(23,500)	(1,044)
Purchases of investments	(69,267)	(337,879)
Proceeds from sale of investments	141,513	1,277,603
NET CASH PROVIDED BY		
INVESTING ACTIVITIES	48,746	938,680
CASH FLOWS FROM FINANCING ACTIVITIES	40,740	958,080
Capital lease principal reductions		(443)
NET CASH USED IN FINANCING ACTIVITIES	-	(443)
NET INCREASE IN CASH		
AND CASH EQUIVALENTS	267,679	847,654
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	1,772,843	925,189
CASH AND CASH EQUIVALENTS, END OF YEAR	\$2,040,522	\$1,772,843

NOTE A – NATURE OF ACTIVITIES

CURE Childhood Cancer, Inc. (CURE) is a nonprofit organization CURE is dedicated to conquering childhood cancer through funding targeted research and through support of patients and their families. CURE was incorporated on November 26, 1975 under the laws of the state of Georgia. CURE is located in Georgia; substantially serves Georgia; and, is substantially supported through grants and contributions. Program activities include the following:

Research – CURE is focused on supporting childhood cancer experts, locally and nationally, who are working daily to discover the ultimate solution. While most organizations are focused on treatment, facilities, education or a program related to what today's knowledge and medicine can offer, CURE is focused on expanding the platform of research to uncover new treatments that speed healing, are less invasive and less damaging, and that can eradicate the cancer itself. CURE has close co-operative relationships with many international and national groups involved in childhood cancer including The National Institute of Health, The National Cancer Institute, and The Children's Oncology Group.

Fellowships – Because the future for children with cancer rests on the doctors and researchers who are being trained today, CURE fully funds two pediatric oncology fellows and building towards endowing a third at the Emory University School of Medicine. CURE believes it is crucial to have new teams of skilled researchers prepared to carry on the search for the cure.

Education – CURE is committed to furthering education on issues surrounding childhood cancer. We publish The CURE Report three times each year and we publish a monthly electronic newsletter. We have a robust education program directed to survivorship and wellness of our families and directed to educating the public about childhood cancer, research and the needs of families.

Patient and Family Support – CURE supports children with cancer and their families as well as the frontline caregivers whose compassionate care and skill are instrumental to a child's health and healing. *Early Outreach* assists families with a new diagnosis in facing their fear and anxiety by providing practical information, encouragement, and other items useful to families throughout their journey. *Critical Needs Care* is dedicated to addressing the most critical and urgent needs of childhood cancer patients and their families. *Family Emergency Funds* provide emergency financial assistance; *Open Arms* delivers meals to both the Egleston and Scottish Rite campuses of the AFLAC Cancer Center at Children's Healthcare of Atlanta and Children's Memorial Hospital of Savannah (CMH); *Bereavement Care* provides essential bereavement support to families who have lost a child to cancer; and, *Partners in Caring counseling program that provides professional counseling services to families at minimal to no cost. <i>Caring for the Caregiver* is aimed at addressing the emotional strain felt by the frontline caregivers of children with cancer and their families at the two campuses of CHOA and CMH.

NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Advertising	Advertising costs and media campaigns are expensed as paid which approximates when an advertisement first takes place; or when the program production and related broadcasting is completed. During the fiscal years ended June 30, 2016 and 2015, CURE expensed advertising and media campaign costs approximating \$149,000 and \$140,000 respectively.
Accounts Receivable	Accounts receivable are stated at the amount management expects to collect from outstanding balances. Balances that are still outstanding after management has used reasonable collection efforts are written off.
Cash and Cash Equivalents	CURE considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Contributions and Donations	In-kind support is recognized for professional services received if those services (a) create or enhance long-lived assets, or (b) require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation.
	Donations of tangible assets are recognized at fair market value when received. The amounts reflected in the accompanying financial statements as in-kind support are offset by like amounts included in expenses or assets.
	Contributions are recorded at fair market value as unrestricted, temporarily restricted, or permanently restricted support depending on the existence and/or nature of any donor restrictions. When the donor restriction expires, that is, when a stipulated time restriction ends or purpose is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and are reported in the statement of activities as net assets released from restrictions.
Receivables	
from Estate	Receivables from estates are recognized as contribution revenue in the period CURE receives notification that the court has deemed the will of the donor's estate to be valid and all conditions have been substantially met and are stated at the amount which management estimates to collect.
Grants Payable	CURE records a liability for grants when they have been approved by the Board of Directors and communicated to the grantees. Grants which are conditional are recorded as liabilities when the conditions to the grants have been substantially met. CURE evaluates the facts and circumstances to determine if a discount related to grants payable is necessary.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Functional Expense

Allocations

Costs of providing programs and services have been summarized on a functional basis on the Statement of Activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

Income Taxes CURE is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is not classified as a private foundation within the meaning of Section 509(a) of the Internal Revenue Code. CURE is also exempt from Georgia income taxes. Income which is not related to exempt purposes, less applicable deductions, is subject to federal and Georgia corporate income taxes. For the years ended June 30 2016 and 2015, CURE did not have any net unrelated business income.

Management of CURE considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential significant changes that management believes are more likely than not to occur, including changes to its status as a not-for-profit entity. Management believes CURE met the requirements to maintain its tax-exempt status and has no income subject to unrelated business income tax; therefore no provision for income taxes has been provided in these financial statements. CURE's income tax returns for the past three years are subject to examination by tax authorities, and may change upon examination.

Investments Investments are accounted for in accordance with authoritative guidance which states that investments in equity securities with readily determinable fair market values and all debt securities should be reported at fair market value with gains and losses included in the statement of activities.

Investments are made according to the Investment Policy Statements adopted by CURE's Board of Directors. These guidelines provide for investments in equities, fixed income, and other securities with performance measured against appropriate indices. Outside parties are contracted by CURE for the purpose of providing investment management and consulting.

Fair Value Measurement

CURE measures fair value at the price that would be received upon sale of an asset, or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Fair Value Measurement -continued	Authoritative guidance establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values, requiring that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted market prices for identical assets or liabilities in active markets.
	Level 2: Unadjusted quoted market prices for similar assets and liabilities in active markets, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.
	Level 3: Significant unobservable inputs for the asset or liability.
	Management has determined that the carrying values of cash, receivables, investments, other assets, accounts payable, accrued expenses, grants payable, refundable advances, and Family Funds Held in Trust approximate fair value.
Net Assets	CURE reports information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets.
Property and Equipment	Property and equipment are carried at cost except for donated items, which are recorded at estimated fair market value when donated. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 5 to 7 years. Expenditures of \$1,000 or more for major renewals and betterments which increase the value or materially extend the life of the related assets are capitalized. Expenditures for maintenance and repairs are expensed as incurred.
Unconditional Promises to Give	Promises to give are recognized as support when the donor makes a promise to give to CURE that is, in substance, unconditional. Promises to give that are expected to be collected within one year are recorded at their net realizable value. Promises to give that are expected to be collected in future years are recorded at the present value of estimated future cash flows. The discounts on these amounts are computed using a risk-free interest rate applicable to the year in which the pledge is made.

NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

effect on total net assets.

issued.

Use of Estimates	Management uses estimates and assumptions in preparing financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing the financial statements.
Reclassifications	Certain amounts in the 2015 financial statements have been reclassified to conform to the 2016 classifications. These reclassifications have no material

Subsequent Events CURE evaluated subsequent events for potential required disclosures through – January 6, 2017 which is the date the financial statements were available to be

NOTE C – INVESTMENTS

The following table summarizes CURE's investments at their fair value measurements, all of which are Level 1 investments, in accordance with authoritative guidance as of June 30:

	2016	2015
Government Obligations	\$157,198	\$158,709
Domestic Debt Mutual Funds	153,140	109,737
Hedged Mutual Funds	257,311	260,555
Domestic Equity Mutual Funds	197,904	188,171
International Equity Mutual Funds	129,740	161,882
Commodity Mutual Funds	82,821	94,482
Domestic Public Real Estate Mutual Funds		49,624
Total Investments	\$978,114	\$1,023,160
Marketable Securities, above	\$978,114	\$1,023,160
Cash and Cash Equivalents	848,332	847,358
Total Investment Portfolio	\$1,826,445	\$1,870,518

NOTE D - ENDOWMENT

CURE's endowment includes one donor-restricted endowment fund and a quasi-endowment fund designated by the Board of Directors to function similarly to an endowment. As required by generally accepted accounting principles (GAAP), net assets associated with endowment funds, including funds designated by the Board of Directors to function similarly to an endowment, are classified and reported based on the existence or absence of donor-imposed restrictions.

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Donor-restricted		\$13,714	\$17,800	\$31,514
Board-designated	\$1,794,931			1,794,931
Total	\$1,794,931	\$13,714	\$17,800	\$1,826,445
Endowment Net Asset (Composition by Type of	Fund as of June 3	0, 2015:	
Donor-restricted		\$13,015	\$17,800	\$30,815
Board-designated	\$1,814,334			1,814,334
Total	\$1,814,334	\$13,015	\$17,800	\$1,845,149

Endowment Net Asset Composition by Type of Fund as of June 30, 2016:

NOTE D - ENDOWMENT - (continued)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Endowment net assets,				
at June 30, 2014	\$2,149,263	\$12,133	\$17,800	\$2,179,196
Investment return:				
Investment income	52,021	882		52,903
Net appreciation (depreciation)			
(realized and unrealized)	(69,542)			(69,542)
Investment fees	(17,408)			(17,408)
Total investment return	(34,929)	882		(34,047)
Endowment assets appropriated				
for expenditure	(300,000)			(300,000)
Endowment net assets,				
at June 30, 2015	\$1,814,334	\$13,015	\$17,800	\$1,845,149
Investment return:				
Investment income	36,026	699		36,725
Net appreciation (depreciation)				
(realized and unrealized)	(39,114)			(39,114)
Investment fees	(16,315)			(16,315)
Total investment return	(19,403)	699		(18,704)
Endowment assets appropriated				
for expenditure	None			None
Endowment net assets,				
at June 30, 2015	\$1,794,931	\$13,714	\$17,800	\$1,826,445

NOTE D - ENDOWMENT - (continued)

Interpretation of Relevant Law

The Board of Directors has interpreted the State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, CURE classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, and (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted net assets until those amounts are appropriated for expenditure by the organization in a manner consistent with the standard of prudence prescribed by SPMIFA. In accordance with SPMIFA, the organization considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the organization and the donor-restricted endowment fund
- 3. General economic conditions
- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. Other resources of the organization
- 7. The investment policies of the organization.

Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or SPMIFA requires the organization to retain as a fund of perpetual duration. In accordance with GAAP, deficiencies of this nature are reported in unrestricted net assets. There were no such deficiencies as of June 30, 2016 or 2015.

Return Objectives and Risk Parameters

CURE has adopted investment and spending policies for endowment assets that strive to expand the purchasing power of the endowment fund (Fund) while providing for distributions based on its spending policy. Endowment assets include those assets of donor-restricted funds that the organization must hold in perpetuity or for a donor-specified period as well as board-designated funds. Under this policy, as approved by the Directors, the endowment assets are invested in a manner that is intended to produce results that approximate the stated spending objectives plus the consumer price index assuming a moderate level of investment risk. Actual returns in any given year may vary from this amount with the primary objective for the Fund being preservation and growth of principal.

Strategies Employed for Achieving Objectives

To satisfy its long-term rate-of-return objectives, CURE relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends).

NOTE D - ENDOWMENT - (continued)

Strategies Employed for Achieving Objectives – (continued)

The Organization targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives within prudent risk constraints.

Spending Policy and How the Investment Objectives Relate to Spending Policy

CURE has a policy of distributing annually 5 percent of the endowment fund's pervious 12 month average balance. However, the Board of Directors have the right in any given year to spend any amount in excess or below this stated amount, as they deem appropriate. The Board has set a minimum balance for the fund at \$1,000,000. The fund can be reduced below this threshold only with approval from both the Finance Committee and the Executive Committee.

NOTE E- INTANGIBLE ASSETS

At June 30, 2016 intangible assets included website development at \$23,500 which was placed in service subsequent to the fiscal year; and fully amortized software totaling \$1,014. At June 30, 2015 it included software at \$1,014 with accumulated amortization of \$817. Software amortization was determined based on the straight-line method over 36 months; and, website development will be amortized on a similar basis.

NOTE F – FAMILY FUNDS HELD IN TRUST

From time to time CURE enters into agreements to receive and administer funds on behalf of families impacted by pediatric cancer. Agreements have a three-year term and may be extended by mutual agreement; upon expiration or termination any unused funds are then considered a donation to CURE. As of June 30, 2016 there are no family funds maintained at CURE.

NOTE G- TEMPORARILY RESTRICTED NET ASSETS

Temporarily restricted net assets include the following as of June 30,	2016	2015	
Patient and Family Support	\$537		
Meli Arant Memorial Research Fund -			
Unappropriated Income	13,714	13,015	
	\$14,251	\$13,015	

NOTE H-PERMANENTLY RESTRICTED NET ASSETS

In 1988 the Meli Arant Memorial Research Fund (The Fund) was established to honor the memory of Raymel Eugenial (Meli) Arant. The Fund was established as a perpetual fund and is maintained in the amount of cumulative gifts made to the Fund. Income shall be used to support leukemia research and such other related purposes deemed appropriate.

NOTE I– OPERATING LEASE

CURE leases certain office equipment and office space under noncancellable leases. Future minimum lease payments are:

For the Year Ended		
June 30,	Amounts	
2017	\$97,779	
2018	1,022	

For the year ended June 30, 2016 and 2015 rent expense was \$86,044 and \$77,709, respectively. Deferred lease incentives represent waived rent that is recognized ratably over the term of the lease; the lease deferral recognized during each year ended June 30, 2016 and 2015 was \$10,577 and \$8,771.

As of January 6, 2017 CURE is in the process of negotiating a lease for new office space.

NOTE J-ALLOCATION OF JOINT COSTS

During the fiscal year ended June 30, 2016 and 2015, CURE conducted activities that included requests for contributions, as well as program components. The costs of conducting certain events included joint costs which are not specifically attributable to particular components of the activities. These joint costs were allocated as follows:

	2016	2015	
Fundraising	\$21,890	\$38,259	
Program: Patient and Family Support	50,750	39,369	
Total	\$72,640	\$77,628	

NOTE K- RETIREMENT PLAN

CURE sponsors a SIMPLE IRA Plan for its employees. During the year ended June 30, 2016 and 2015, respectively, matching contributions approximated \$20,500 and \$17,300.

NOTE L- CONCENTRATIONS

CURE maintains its cash balances in financial institutions insured by the Federal Deposit Insurance Corporation (FDIC) up to \$250,000. At June 30, 2016 and 2015, respectively, amounts held at financial institutions in excess of the FDIC limits approximated \$1,222,700 and \$721,000. These concentrations are substantially related to the timing of the Believe Ball held in late Spring and the anticipated payout of substantial grant awards in July of each year.

During the fiscal years ended June 30, 2016 and 2015, CURE generated approximately 16% and 15%, respectively, of its total support and revenue from fundraising activities attributable to one event.

NOTE M- RELATED PARTY TRANSACTIONS

During the year ended June 30, 2016 and 2015, respectively, CURE received donations approximating \$265,000 and \$420,000 from board members, their related entities, or from donor advisor funds directed by them.

During the fiscal years ended June 30, 2016 and 2015, CURE received marketing services through a business in which a current Board Member is a majority owner. The amounts paid for those services, including the applicable pass-through expenses paid by them to other providers, approximated \$305,500 and \$230,000 for 2016 and 2015, respectively. During the fiscal year ended June 30, 2015, CURE compensated a board member approximately \$24,000 for special event coordination services.

NOTE N – DONATED GOODS AND SERVICES

The community provides in-kind goods and services throughout the year in support of the various activities conducted by CURE. Following are the functional allocations.

For the fiscal year ended June 30,	2016	2015
Special Event Direct Participant Benefits	\$32,100	
Fundraising	33,769	\$5,500
General and Administration	2,000	
Program:		
Patient and Family Support	167,783	111,708
— 1		
Total	\$235,652	\$117,208

NOTE O- GRANTS PAYABLE AND OTHER COMMITMENTS

Funding commitments are approved by CURE's Board of Directors based on recommendations provided by CURE's Scientific Advisory Council. Upon notification to grant recipients, CURE reports as a grant payable those awards that are in substance unconditional. At June 30, 2016 grants are due and payable as follows:

During the year ended June 30,	2017	
Children's Healthcare of Atlanta/Emory University	\$138,945	
Children's Cancer Therapy Development Institute	81,281	
Total	\$220,226	

Commitments to The AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta for the fiscal year ending June 30, 2017 are \$1,586,127. In addition, on July 13, 2016 CURE committed \$1,153,313 to other organizations.